Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (REGN) reported a 30% revenue increase to $2.42 billion in Q4 2020, with EYLEA® U.S. net sales at $1.34 billion (+10%) and Dupixent® global sales at $1.17 billion (+56%). GAAP diluted EPS rose 48% to $10.24. The REGEN-COV™ antibody cocktail received FDA Emergency Use Authorization, with a new agreement for 1.25 million doses worth $2.625 billion. The company anticipates continued growth in 2021 through EYLEA, Dupixent, and Libtayo, with several regulatory reviews pending.
Regeneron Pharmaceuticals and Sanofi announced new analyses highlighting the efficacy of Dupixent® (dupilumab) in treating diseases driven by type 2 inflammation, including asthma, atopic dermatitis, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyposis. The results, to be presented at the AAAAI Virtual Annual Meeting from February 26 to March 1, demonstrate significant improvements in patients' symptoms across multiple studies. Dupixent, a fully-human monoclonal antibody, targets IL-4 and IL-13 signaling, vital in managing type 2 inflammatory diseases.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced confirmation from Columbia University researchers that its REGEN-COV antibody cocktail neutralizes SARS-CoV-2 variants from the UK and South Africa. Published data indicates REGEN-COV retains effectiveness against these variants, with further studies ongoing for additional mutations. The cocktail features two monoclonal antibodies, imdevimab and casirivimab, designed to block virus infectivity. Regeneron is enhancing global supply through collaboration with Roche and is prepared to develop new antibody combinations to combat future variants.
Regeneron Pharmaceuticals reported positive initial results from a Phase 3 trial of REGEN-COV, an antibody cocktail for preventing COVID-19. The study showed a 100% prevention rate of symptomatic infections in high-risk individuals, and a 50% reduction in overall infections compared to placebo. Infections in the treatment group were asymptomatic with markedly lower viral loads and shorter durations of shedding. Safety assessments indicated fewer adverse events with REGEN-COV, and the injection method offers greater convenience. Full Phase 3 results are expected early Q2 2021.
Regeneron Pharmaceuticals and the Society for Science have announced the 2021 finalists for the Regeneron Science Talent Search, recognizing 40 exceptional high school seniors from a pool of 1,760 entrants. These finalists, selected for their scientific projects, will compete for over $1.8 million in awards during a virtual event March 10-17, 2021. Notable projects include studies on COVID-19 diagnostics and e-cigarette impacts on COPD. Each finalist will receive at least $25,000, with top prizes reaching $250,000.
On January 21, 2021, Regeneron Pharmaceuticals (NASDAQ: REGN) and the Society for Science announced the finalists for the Regeneron Science Talent Search 2021, highlighting 40 outstanding high school seniors selected from 1,760 entrants. They will compete for over $1.8 million in awards during a virtual competition from March 10-17, 2021. Finalists’ projects cover diverse STEM fields, addressing critical issues such as COVID-19 diagnostics and environmental concerns. Each finalist receives at least $25,000, with top awards reaching $250,000. This initiative fosters innovation and encourages young scientists.
Regeneron Pharmaceuticals (NASDAQ: REGN) will announce its fourth quarter and full year 2020 financial results on February 5, 2021, before U.S. markets open. A conference call will occur at 8:30 AM ET the same day, accessible by dialing (888) 660-6127 for U.S. callers or (973) 890-8355 for international participants, using conference ID 1580376. A webcast link will be available on their Investors and Media page. Regeneron is renowned for its innovations in biotechnology, focusing on treatments for serious diseases.
Regeneron Pharmaceuticals has announced a new agreement with the U.S. government to provide an additional 1.25 million doses of the casirivimab and imdevimab antibody cocktail, increasing the total potential supply to over 1.5 million doses. The antibody cocktail aims to treat high-risk patients with mild to moderate COVID-19 and is being supplied under FDA Emergency Use Authorization.
The government will purchase the doses at an estimated value of up to $2.625 billion, with 750,000 doses expected by June 30, 2021.
Regeneron Pharmaceuticals has revealed promising initial data from its Phase 1/2/3 trial of the antibody cocktail, casirivimab and imdevimab, for hospitalized COVID-19 patients. The data indicates a lower risk of death or mechanical ventilation in seronegative patients, achieving a hazard ratio of 0.78. These patients showed significant viral load reductions, with declines reaching -0.54 log10 copies/mL by day 7. While no serious adverse events were significant, the study emphasizes the impact of pre-existing immunity. The trial continues alongside the UK RECOVERY trial, with ongoing evaluations needed for conclusive results.
Regeneron Pharmaceuticals announced the publication of initial clinical data on its antibody cocktail, casirivimab and imdevimab, in the New England Journal of Medicine. This Phase 1/2/3 trial involved 275 patients and demonstrated significant reduction in viral load and need for medical visits in non-hospitalized COVID-19 patients. The treatment is available under Emergency Use Authorization, with follow-on data from 799 patients further validating its effectiveness, particularly in individuals without pre-existing antibodies.
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
What is the market cap of Regeneron Pharmaceuticals (REGN)?
What types of diseases does Regeneron Pharmaceuticals focus on?
What are some of Regeneron's key products?
Who are some of Regeneron's notable collaborators?
What recent financial steps has Regeneron taken?
How does Regeneron leverage genetic medicine?
What is the significance of Eylea in Regeneron's product portfolio?
What advancements has Regeneron made in gene therapy?
What is Dupixent used for?
What technologies does Regeneron use for drug development?
How does Regeneron contribute to scientific discovery?
